A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

StatusTerminated
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial terminated Sponsor's reason: Sponsor's Decision Show 4 more changesShow less
    • Final enrollment: 17 participants (planned 128)
    • Primary completion date changed from estimate of Nov 15, 2027 to Aug 18, 2026
    • Study sites: 7 to 6
    • Eligibility criteria expanded, about 29 words
  2. 3 versions Re-verified since Jul 2, 2026, no change to tracked fieldsv25-v27
  3. Phase changed: Phase 1/2 → Phase 1
    • Study sites revised (7)
    v24
  4. Re-verified, no change to tracked fieldsv23
  5. Study sites revised (7)v22
Show 20 earlier versionsHide 20 earlier versions
  1. Re-verified, no change to tracked fieldsv21
  2. Phase: Phase 1 to Phase 1/2
    • Primary and study completion dates: Jul 15, 2027 to Nov 15, 2027
    v20
  3. 2 versions Re-verified since Jan 12, 2026, no change to tracked fieldsv18-v19
  4. Primary endpoints revised (2)
    • Eligibility criteria expanded, about 143 words
    • Secondary endpoints revised (6)
    v17
  5. Phase: Phase 1/2 to Phase 1
    • Primary and study completion dates: Feb 27, 2026 to Jul 15, 2027
    v16
  6. Study sites: 6 to 7v15
  7. Phase: Phase 1 to Phase 1/2
    • Study sites: 3 to 6
    v14
  8. Phase: Phase 1/2 to Phase 1v13 Show 4 more changesShow less
    • Study sites: 2 to 3
    • Eligibility criteria expanded, about 24 words
    • Secondary endpoints revised (6)
    • Primary endpoints revised (2)
  9. Primary completion date: Mar 15, 2026 to Feb 27, 2026
    • Study completion date: Sep 15, 2026 to Feb 27, 2026
    v12
  10. 3 versions Re-verified since Apr 10, 2025, no change to tracked fieldsv9-v11
  11. Site details revised at 1 of 2 sitesv8
  12. Phase: Phase 1 to Phase 1/2
    • Eligibility criteria expanded, about 33 words
    v7
  13. Phase: Phase 1/2 to Phase 1v6
  14. Study sites: 1 to 2v5
  15. Primary completion date: Jan 15, 2026 to Mar 15, 2026
    • Study completion date: Mar 15, 2026 to Sep 15, 2026
    v4
  16. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 31, 2024 to Nov 18, 2024
    v3
  17. Phase: Phase 1 to Phase 1/2v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Roche/Genentech
368 trials monitored
See 30 trials at risk
COPD
1,120 trials monitored
See 35 trials at risk
This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.
Trial Details
NCT Number NCT06603246
Lead Sponsor Genentech, Inc.
Conditions
(from sponsor)		 Non-cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease
Related terms Pulmonary Disease, Chronic Obstructive
Enrollment 17 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov